ERLEADA (apalutamide) is an androgen‑receptor inhibitor for treating metastatic castration‑sensitive and non‑metastatic castration‑resistant prostate…
ERLEADA® is prescribed as a 240 mg oral tablet taken once daily, either with or without food. The tablet contains 60 mg of apalutamide per pill and may be reduced to 180 mg or 120 mg if toxicity of grade 3 or higher occurs.
The drug is indicated for adult men with metastatic castration‑sensitive prostate cancer (mCSPC) and high‑risk non‑metastatic castration‑resistant prostate cancer (nmCRPC). Reimbursement requires prior approval, pathology reports, and regular PSA monitoring. Common adverse reactions include rash, which should be managed with topical steroids or antihistamines and may require temporary discontinuation. This manual is written in Chinese.
| Recommended dosage | 240 mg once daily |
|---|---|
| Tablet strength | 60 mg per tablet |
| Dose reduction options | 180 mg or 120 mg |
| Active ingredient | Apalutamide |
The recommended dosage is 240 mg taken orally once a day.
Approximately 30 % of patients develop a rash, most of which resolve within two months; severe rash may require dose reduction or discontinuation.